Method of identifying a status of a mucosal intestinal epithelial barrier to improve treatment of inflammatory bowel disease
US10663473B2 · kind B2 · utility
Assignee
Inventor
Key dates
| Filing date | Feb 2, 2017 |
| Grant date | May 26, 2020 |
| Priority date | — |
| Expiry date | Feb 2, 2037 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/52
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
In some embodiments, the invention provides a method for identifying an agent beneficial to treat a patient with inflammatory bowel disease comprising: a) determining a status of an intestinal barrier in the patient; and b) categorizing the status as severe dysfunction or moderate dysfunction, wherein a patient categorized as having severe dysfunction is identified as a patient who will benefit from treatment with an agent selected from the group consisting of an anti-TNF agent and/or an anti-IL-12/23 agent, and a patient categorized as having moderate dysfunction is identified as a patient who will benefit from treatment with an anti-integrin agent, an anti-janus kinase agent, and/or and a sphingosine-1-phosphate receptor agonist agent.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.